CAJ | 학술논문

目的探讨检测血浆甲基化Sept9基因(mSEPT9)在结直肠癌患者诊断中的临床意义.方法将试验对象分为3组,即结直肠癌组79例、结直肠息肉组73例和健康对照组146名.应用PCR荧光探针法检测外周血浆中mSEPT9,分析该基因阳性率与结直肠临床病理特征的关系,并与CEA和(或)CA19-9阳性率作比较.统计学分析采用卡方检验或连续性校正的卡方检验.结果结直肠癌组血浆m SEP T9阳性率为71.05％(54/76),结直肠息肉组为5.80％(4/69),健康对照组为3.68％(5/136),结直肠癌组mSEPT9阳性率明显高于其他两组(x2=141.700,P＜0.01).血浆mSEPT9在结直肠癌患者中的敏感度为71.05％,特异度为95.61％.在结直肠肿瘤最大径＞5.0 cm、病灶侵及浆膜层或周围组织、组织病理分型为腺癌、临床分期为Ⅳ期的患者中,血浆mSEPT9阳性率较高,分别为88.46％(23/26)、78.57％(44/56)、74.63％(50/67)和8/10,差异均有统计学意义(x2=6.635、8.661、3.333、10.969,P均＜0.05).与血清其他肿瘤标志物相比,结直肠癌患者血浆mSEPT9阳性率明显高于CEA、CA19-9及联合检测CEA、CA19-9的阳性率,分别为71.05％(54/76)、34.21％(26/76)、18.42％(14/76)、40.79％(31/76),两两比较差异均有统计学意义(x2=20.689、42.577、14.119,P均＜0.01).结论结直肠癌患者血清mSEP T9阳性率明显增高,检测该基因在结直肠癌的诊断中具有重要的临床意义.
목적 탐토검측혈장갑기화Sept9기인(mSEPT9)재결직장암환자진단중적림상의의.방법 장시험대상분위3조,즉결직장암조79례、결직장식육조73례화건강대조조146명.응용PCR형광탐침법검측외주혈장중mSEPT9,분석해기인양성솔여결직장림상병리특정적관계,병여CEA화(혹)CA19-9양성솔작비교.통계학분석채용잡방검험혹련속성교정적잡방검험.결과 결직장암조혈장m SEP T9양성솔위71.05％(54/76),결직장식육조위5.80％(4/69),건강대조조위3.68％(5/136),결직장암조mSEPT9양성솔명현고우기타량조(x2=141.700,P＜0.01).혈장mSEPT9재결직장암환자중적민감도위71.05％,특이도위95.61％.재결직장종류최대경＞5.0 cm、병조침급장막층혹주위조직、조직병리분형위선암、림상분기위Ⅳ기적환자중,혈장mSEPT9양성솔교고,분별위88.46％(23/26)、78.57％(44/56)、74.63％(50/67)화8/10,차이균유통계학의의(x2=6.635、8.661、3.333、10.969,P균＜0.05).여혈청기타종류표지물상비,결직장암환자혈장mSEPT9양성솔명현고우CEA、CA19-9급연합검측CEA、CA19-9적양성솔,분별위71.05％(54/76)、34.21％(26/76)、18.42％(14/76)、40.79％(31/76),량량비교차이균유통계학의의(x2=20.689、42.577、14.119,P균＜0.01).결론 결직장암환자혈청mSEP T9양성솔명현증고,검측해기인재결직장암적진단중구유중요적림상의의.
Objective To explore the clinical significance of testing serum methylated Sept9 gene (mSEPT9) in diagnosis of colorectal cancer.Methods The subjects were divided into three groups,79 cases in colorectal cancer group,73 cases in colorectal polyps group and 146 cases in healthy control group.The mSEPT9 in peripheral blood serum were detected by the polymerase chain reaction (PCR) fluorescence probe method.The relation between positive rate of the gene and clinical pathological characteristics of colorectal cancer was analyzed.Furthermore the positive rate was compared with that of carcinoembryonic antigen (CEA) and (or) carbohydrate antigen 19-9 (CA19-9).Chi-square test and Chisquare test with continuity correction were performed for statistical analysis.Results The positive rate of mSEPT9 was 71.05％ (54/76),5.80％ (4/69) and 3.68％ (5/136),in plasma of colorectal cancer group,colorectal polyps group,and healthy control group,respectively.The positive rate of mSEPT9 of colorectal cancer group was significantly higher than that of the other two groups (x2=141.700,P＜ 0.01).The sensitivity and specificity of serum mSEPT9 in detecting patients with colorectal cancer was 71.05 ％ and 95.61％,respectively.The positive rate of mSEPT9 was higher in patients with colorectal tumor over 5.0 cm,serosa layer or surrounding tissue invaded by the lesions,adenocarcinoma and clinical stage Ⅳ,which was 88.46％ (23/26),78.57％ (44/56),74.63％ (50/67) and 8/10,respectively,and the differences were statistically significant (x2 =6.635,8.661,3.333 and 10.969,all P＜0.05).Compared with other serum tumor markers,the positive rate of mSEPT9 was higher than that of CEA,CA19-9 alone and CEA,CA19-9 joint detection in patients with colorectal cancer,which was 71.05 ％ (54/ 76),34.21％ (26/76),18.42％ (14/76) and 40.79％ (31/76),respectively.The differences were statistically significant (x2 =20.689,42.577 and 14.119,all P＜0.01).Conclusions The positive rate of mSEPT9 was high in plasma of patients with colorectal cancer.The detection of this gene played an important role in the diagnosis of colorectal cancer.